Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, October 29, 2021
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
[ Fri, Oct 29th 2021
] - WOPRAI
David Lebovitz Maintained (BPMC) at Hold with Increased Target to $111 on, Oct 29th, 2021
David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $96 to $111 on, Oct 29th, 2021.
David has made no other calls on BPMC in the last 4 months.
There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Thursday, October 28th, 2021
